Libtayo scores second OK in two weeks, this time for front-line NSCLC. Can it take on Keytruda?

Coming up behind the other major PD-1 players, Regeneron sought to create its own market for Libtayo by going into indications where others have yet to venture — a strategy CSO George Yancopoulos likes to boast about. Now, the drug can directly compete against the heavyweights with its third approval.